Tenderwize
Back to tender search

Open house drug discount agreements Ranibizumab injection solution vial

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 05, 2027 · 201 days left·Open·Supplies·Framework
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ranibizumab in der Darreichungsform Injektionslösung in der Durchstechflasche, ATC S01LA04

60/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

60 / 100

Complexity

20 / 100

Risk factors

No value or volume estimates available; may attract many participants, diluting potential benefit.

Open-house agreements automatically terminate if a standard competitive discount agreement for the same substance is si...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Supply of Ranibizumab (ATC S01LA04) in injection solution form in vial
  • Participation in a non-exclusive drug discount scheme with AOK Bayern
Show full summary

This is an open-house model for non-exclusive drug discount agreements (Rabattverträge) for the active substance Ranibizumab (injection solution, vial, ATC S01LA04) with AOK Bayern. It is not a traditional procurement procedure; any eligible pharmaceutical company can join under identical, non-negotiable terms. The contract period is from 1 May 2025 to 30 April 2027, with possible early termination. No estimated value is published. Only one lot is identified.

Risks

No value or volume estimates available; may attract many participants, diluting potential benefit.

Open-house agreements automatically terminate if a standard competitive discount agreement for the same substance is si...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Eligibility

  • Only pharmaceutical companies are eligible to participate

Administrative

  • Must submit a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
  • Contract, annex specifying covered medicines, and self-declaration must be submitted in paper (2 copies) or electronically with qualified electronic signature

Requirements may be incomplete.

Buyer

Location

München, DEU

Website

www.aok.de

Buyer profile

Open profile

Identifier

DE811695320

Activity

Health

Lots (1)

LOT-0001

Open house drug discount agreements Ranibizumab injection solution vial

Non-exclusive discount agreements for Ranibizumab injection solution in vial form. All interested pharmaceutical companies meeting eligibility can sign identical contracts.

SuppliesFrameworkEU fundedElectronic submission

Location

DE212, Germany

Duration

Apr 2025 - Apr 2027

Category

Pharmaceutical products

Deadline

Deadline Mar 05, 2027

Procurement Details

Publication date
18 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
176237-2025

Documents (2)

Similar tenders